These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 26648056)
1. Common and Distinct Interactions of Chemical Inhibitors with Cytochrome P450 CYP1A2, CYP2A6 and CYP2B6 Enzymes. Raunio H; Juvonen RO; Poso A; Lahtela-Kakkonen M; Rahnasto-Rilla M Drug Metab Lett; 2016; 10(1):56-64. PubMed ID: 26648056 [TBL] [Abstract][Full Text] [Related]
2. CYP2B6 Genotype-Dependent Inhibition of CYP1A2 and Induction of CYP2A6 by the Antiretroviral Drug Efavirenz in Healthy Volunteers. Metzger IF; Dave N; Kreutz Y; Lu JBL; Galinsky RE; Desta Z Clin Transl Sci; 2019 Nov; 12(6):657-666. PubMed ID: 31339646 [TBL] [Abstract][Full Text] [Related]
3. Site-specific oxidation of flavanone and flavone by cytochrome P450 2A6 in human liver microsomes. Nagayoshi H; Murayama N; Kakimoto K; Takenaka S; Katahira J; Lim YR; Kim V; Kim D; Yamazaki H; Komori M; Guengerich FP; Shimada T Xenobiotica; 2019 Jul; 49(7):791-802. PubMed ID: 30048196 [TBL] [Abstract][Full Text] [Related]
4. Enantioselective inhibition of Cytochrome P450-mediated drug metabolism by a novel antithrombotic agent, S002-333: Major effect on CYP2B6. Bhateria M; Ramakrishna R; Puttrevu SK; Saxena AK; Bhatta RS Chem Biol Interact; 2016 Aug; 256():257-65. PubMed ID: 27387538 [TBL] [Abstract][Full Text] [Related]
5. Lim SYM; Alshagga MA; Alshawsh MA; Ong CE; Pan Y Drug Metab Pers Ther; 2021 Aug; 37(1):55-67. PubMed ID: 35146975 [TBL] [Abstract][Full Text] [Related]
6. Understanding a substrate's product regioselectivity in a family of enzymes: a case study of acetaminophen binding in cytochrome P450s. Yang Y; Wong SE; Lightstone FC PLoS One; 2014; 9(2):e87058. PubMed ID: 24498291 [TBL] [Abstract][Full Text] [Related]
7. Identification of inhibitors of the nicotine metabolising CYP2A6 enzyme--an in silico approach. Rahnasto M; Wittekindt C; Juvonen RO; Turpeinen M; Petsalo A; Pelkonen O; Poso A; Stahl G; Höltje HD; Raunio H Pharmacogenomics J; 2008 Oct; 8(5):328-38. PubMed ID: 17923852 [TBL] [Abstract][Full Text] [Related]
8. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype. Kiang TK; Ho PC; Anari MR; Tong V; Abbott FS; Chang TK Toxicol Sci; 2006 Dec; 94(2):261-71. PubMed ID: 16945988 [TBL] [Abstract][Full Text] [Related]
9. Use of Phenoxyaniline Analogues To Generate Biochemical Insights into the Interactio n of Polybrominated Diphenyl Ether with CYP2B Enzymes. Chen C; Liu J; Halpert JR; Wilderman PR Biochemistry; 2018 Feb; 57(5):817-826. PubMed ID: 29215266 [TBL] [Abstract][Full Text] [Related]
10. Substrates of human cytochromes P450 from families CYP1 and CYP2: analysis of enzyme selectivity and metabolism. Lewis DF; Lake BG; Dickins M Drug Metabol Drug Interact; 2004; 20(3):111-42. PubMed ID: 15508429 [TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and enzymatic characterization of quinazoline-based CYP1A2 inhibitors. Corral PA; Botello JF; Xing C Bioorg Med Chem Lett; 2020 Jan; 30(2):126719. PubMed ID: 31784319 [TBL] [Abstract][Full Text] [Related]
12. DR-predictor: incorporating flexible docking with specialized electronic reactivity and machine learning techniques to predict CYP-mediated sites of metabolism. Huang TW; Zaretzki J; Bergeron C; Bennett KP; Breneman CM J Chem Inf Model; 2013 Dec; 53(12):3352-66. PubMed ID: 24261543 [TBL] [Abstract][Full Text] [Related]
13. Selective inhibitory effects of machilin A isolated from Machilus thunbergii on human cytochrome P450 1A and 2B6. Kim SJ; You J; Choi HG; Kim JA; Jee JG; Lee S Phytomedicine; 2015 Jun; 22(6):615-20. PubMed ID: 26055126 [TBL] [Abstract][Full Text] [Related]
14. In vitro inhibitory mechanisms and molecular docking of 1'-S-1'-acetoxychavicol acetate on human cytochrome P450 enzymes. Haque AKMM; Leong KH; Lo YL; Awang K; Nagoor NH Phytomedicine; 2017 Jul; 31():1-9. PubMed ID: 28606510 [TBL] [Abstract][Full Text] [Related]
15. Functional characterization of single nucleotide polymorphisms with amino acid substitution in CYP1A2, CYP2A6, and CYP2B6 found in the Japanese population. Iwasaki M; Yoshimura Y; Asahi S; Saito K; Sakai S; Morita S; Takenaka O; Inoda T; Kashiyama E; Aoyama A; Nakabayashi T; Omori S; Kuwabara T; Izumi T; Nakamura K; Takanaka K; Nakayama Y; Takeuchi M; Nakamura H; Kametani S; Terauchi Y; Hashizume T; Nagayama S; Kume T; Achira M; Kawai H; Kawashiro T; Nakamura A; Nakai Y; Kagayama A; Shiraga T; Niwa T; Yoshimura T; Morita J; Ohsawa F; Tani M; Osawa N; Ida K; Noguchi K Drug Metab Pharmacokinet; 2004 Dec; 19(6):444-52. PubMed ID: 15681899 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of human cytochrome P450 enzymes by the natural hepatotoxin safrole. Ueng YF; Hsieh CH; Don MJ Food Chem Toxicol; 2005 May; 43(5):707-12. PubMed ID: 15778010 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase. Grimm SW; Dyroff MC Drug Metab Dispos; 1997 May; 25(5):598-602. PubMed ID: 9152599 [TBL] [Abstract][Full Text] [Related]
18. Screening of Human CYP1A2 and CYP3A4 Inhibitors from Seaweed In Silico and In Vitro. Yim SK; Kim K; Chun S; Oh T; Jung W; Jung K; Yun CH Mar Drugs; 2020 Nov; 18(12):. PubMed ID: 33260381 [TBL] [Abstract][Full Text] [Related]
19. In vitro metabolism and drug interaction potential of a new highly potent anti-cytomegalovirus molecule, CMV423 (2-chloro 3-pyridine 3-yl 5,6,7,8-tetrahydroindolizine I-carboxamide). Bournique B; Lambert N; Boukaiba R; Martinet M Br J Clin Pharmacol; 2001 Jul; 52(1):53-63. PubMed ID: 11453890 [TBL] [Abstract][Full Text] [Related]
20. Structural and biophysical characterization of human cytochromes P450 2B6 and 2A6 bound to volatile hydrocarbons: analysis and comparison. Shah MB; Wilderman PR; Liu J; Jang HH; Zhang Q; Stout CD; Halpert JR Mol Pharmacol; 2015 Apr; 87(4):649-59. PubMed ID: 25585967 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]